Takeda posts surprise profit a year after Shire mega-merger

Japan’s Takeda has posted a surprise profit after its $59 billion merger with Shire just over a year ago, as the company shakes off the huge debts it incurred to get the deal done. 

Ferring’s gut microbiome drug clears phase 3 trial in C. dif...

Ferring Pharma has reported what it says is the first positive phase 3 trial of a microbiome therapy – based on healthy bacteria – showing it can reduce recurrences of a seriou

FDA says all ranitidine drugs should be recalled on safety c...

Takeda buys US biotech PvP Biologics for $330 million

Takeda has bought US biotech PvP Biologics for $330 million, adding a potential new form of therapy for coeliac disease to its pipeline.

Takeda buys coeliac drug licence from COUR Pharmaceuticals

Takeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced supportive phase 2a trial data.

AZ sells rights to gastro drug Losec to Cheplapharm in $309m...

AstraZeneca has agreed to sell most global commercial rights to its gastro drug Losec (omeprazole) and associated brands to Germany’s Cheplapharm Arzneimittel in a deal worth up to $309 mil